B
Bull
Bull · 25%IMNN
$0.59
Szenariopreis
$1.600
0.000 (0.00%)Zum Schluss
Loading chart…
- High
- 1.647
- Open
- 1.600
- VWAP
- 1.60
- Vol
- 82.36K
- Mkt Cap
- 10.62M
- Low
- 1.550
- Amount
- 131.69K
- EV/EBITDA, TTM
- 0.00
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
AI analysis of Imunon Inc (IMNN)
buyImunon Inc is a good buy right now due to its recent positive clinical trial results and an analyst price target of $10, which suggests a significant upside from the current price of $1.60. The company has demonstrated a strong potential in its MRD trial, with a 87.5% ctDNA clearance rate, indicating effective treatment outcomes.
Bewertungskennzahlen
The current forward P/E ratio for Imunon Inc (IMNN) is 16.78, compared to its 5-year average forward P/E of 1.54.
Alphio AI Price Scenarios for IMNN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.508-26NewsfilterIMUNON Hosts R&D Day to Showcase IMNN-001 Progress
2.008-12NASDAQ.COMImunon (IMNN) Q2 2026 Earnings Call Transcript
9.508-11NASDAQ.COMIMUNON Reports Q2 2026 Financial Results and Trial Progress
- 9.007-23Newsfilter
IMUNON's IMNN-001 Shows Promise in Ovarian Cancer Research
2.007-21NASDAQ.COMIMUNON Reports Positive Preliminary Data from MRD Trial for Ovarian Cancer
IMNN FAQ — answered by Alphio AI
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Imunon Inc is a good buy right now due to its recent positive clinical trial results and an analyst price target of $10, which suggests a significant upside from the current price of $1.60. The company has demonstrated a strong potential in its MRD trial, with a 87.5% ctDNA clearance rate, indicating effective treatment outcomes.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.